As Eli Lilly gears up for releasing its Q2 earnings today, a key revenue and growth opportunity for the company—obesity drugs, continue to be in the news. In the last few weeks, regulatory agencies in the European Union and the UK have announced investigations into the link between GLP1 receptor agonists to suicidal ideation.

Eli Lilly’s blockbuster, Mounjaro (tirzepatide) is approved as an adjunct to diet and exercise to help patients with type 2 diabetes improve their glycemic control. However, it is currently used off label as an obesity medication, and has a Fast Track designation for official on-label use for that purpose. Moreover, Lilly’s investigational drug retatrutide, which targets GLP-1R, the gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor (GCGR), has also generated significant investor interest for its potential as a weight-loss drug.

In the coming months, sales revenues for these drugs are expected to grow significantly. However, access comes with its own challenges due to drug shortages, and the need to navigate complex reimbursement dynamics.

Additionally, as research on drugs like semaglutide accumulate, others are also debating the additional effects that are often widely shared on social platforms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Our signals coverage is powered by GlobalData’s Disruptor data, which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors. These signals help us to uncover key innovation areas in the sector and the themes that drive them. They tell us about the topics on the minds of business leaders and investors, and indicate where leading companies are focusing their investment, deal-making and R&D efforts.